Alexander Buchberger

Prof. Alexander Buchberger

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2010 in Molecular Cell
Verified
Journal Article
Closed access
ABAlexander Buchberger
Alexander Buchberger
BBBernd Bukau
Bernd Bukau
TSThomas Sommer
Thomas Sommer

29 August 2015 in FEBS Letters
Verified
Journal Article
Closed access
ABAlexander Buchberger
Alexander Buchberger
HSHermann Schindelin
Hermann Schindelin
PHPetra Haenzelmann
Petra Haenzelmann

1 June 2018 in Molecular Cell
Verified
Journal Article
Closed access
ATAnkit Turakhiya
Ankit Turakhiya
SMSusanne R. Meyer
Susanne R. Meyer
GMGabriella Marincola
Gabriella Marincola
SBStefanie Böhm
Stefanie Böhm
JVJens T. Vanselow
Jens T. Vanselow
ABAlexander Buchberger
Alexander Buchberger

23 April 2010 in EMBO Reports
Verified
Journal Article
Open access
PDF file
VFVanesa Fernández‐Sáiz
Vanesa Fernández‐Sáiz
ABAlexander Buchberger
Alexander Buchberger
The ubiquitin‐selective chaperone p97 is involved in major proteolytic pathways of eukaryotic cells and has been implicated in several human proteinopathies. Moreover, mutations in p97 cause the disorder inclusion body myopathy with Paget disease of bone and frontotemporal dementia (IBMPFD). The molecular basis underlying impaired degradation and pathological aggregation of ubiquitinated proteins in IBMPFD is unknown. Here, we identify perturbed co‐factor binding as a common defect of IBMPFD‐causing mutant p97. We show that IBMPFD mutations induce conformational changes in the p97 N domain, the main binding site for regulatory co‐factors. Consistently, mutant p97 proteins exhibit strongly altered co‐factor interactions. Specifically, binding of the ubiquitin ligase E4B is reduced, whereas binding of ataxin 3 is enhanced, thus resembling the accumulation of mutant ataxin 3 on p97 in spinocerebellar ataxia type 3. Our results suggest that imbalanced co‐factor binding to p97 is a key pathological feature of IBMPFD and potentially of other proteinopathies involving p97.

1 November 2011 in Journal of Biological Chemistry
Verified
Journal Article
Open access
CSChristopher Stapf
Christopher Stapf
ECEdward Cartwright
Edward Cartwright
MBMark Bycroft
Mark Bycroft
KHKay Hofmann
Kay Hofmann
ABAlexander Buchberger
Alexander Buchberger
Cellular functions of the essential, ubiquitin-selective AAA ATPase p97/valosin-containing protein (VCP) are controlled by regulatory cofactors determining substrate specificity and fate. Most cofactors bind p97 through a ubiquitin regulatory X (UBX) or UBX-like domain or linear sequence motifs, including the hitherto ill defined p97/VCP-interacting motif (VIM). Here, we present the new, minimal consensus sequence RX(5)AAX(2)R as a general definition of the VIM that unites a novel family of known and putative p97 cofactors, among them UBXD1 and ZNF744/ANKZF1. We demonstrate that this minimal VIM consensus sequence is necessary and sufficient for p97 binding. Using NMR chemical shift mapping, we identified several residues of the p97 N-terminal domain (N domain) that are critical for VIM binding. Importantly, we show that cellular stress resistance conferred by the yeast VIM-containing cofactor Vms1 depends on the physical interaction between its VIM and the critical N domain residues of the yeast p97 homolog, Cdc48. Thus, the VIM-N domain interaction characterized in this study is required for the physiological function of Vms1 and most likely other members of the newly defined VIM family of cofactors.

1 April 2011 in Molecular and Cellular Biology
Verified
Journal Article
Closed access
SBStefanie Böhm
Stefanie Böhm
GLGiorgia Lamberti
Giorgia Lamberti
VFVanesa Fernández-Sáiz
Vanesa Fernández-Sáiz
CSChristopher Stapf
Christopher Stapf
ABAlexander Buchberger
Alexander Buchberger
The chaperone-related AAA ATPase Cdc48 (p97/VCP in higher eukaryotes) segregates ubiquitylated proteins for subsequent degradation by the 26S proteasome or for nonproteolytic fates. The specific outcome of Cdc48 activity is controlled by the evolutionary conserved cofactors Ufd2 and Ufd3, which antagonistically regulate the substrates' ubiquitylation states. In contrast to the interaction of Ufd3 and Cdc48, the interaction between the ubiquitin chain elongating enzyme Ufd2 and Cdc48 has not been precisely mapped. Consequently, it is still unknown whether physiological functions of Ufd2 in fact require Cdc48 binding. Here, we show that Ufd2 binds to the C-terminal tail of Cdc48, unlike the human Ufd2 homologue E4B, which interacts with the N domain of p97. The binding sites for Ufd2 and Ufd3 on Cdc48 overlap and depend critically on the conserved residue Y834 but are not identical. Saccharomyces cerevisiae cdc48 mutants altered in residue Y834 or lacking the C-terminal tail are viable and exhibit normal growth. Importantly, however, loss of Ufd2 and Ufd3 binding in these mutants phenocopies defects of Δufd2 and Δufd3 mutants in the ubiquitin fusion degradation (UFD) and Ole1 fatty acid desaturase activation (OLE) pathways. These results indicate that key cellular functions of Ufd2 and Ufd3 in proteasomal protein degradation require their interaction with Cdc48.